The study by Yang and colleagues, “Chronic Fatigue Syndrome Induced by Environmental Toxic Exposure: Effects of Polyhexamethyleneguanidine Phosphate Exposure on Mitochondrial Function and Neural Health,” represents an important development in environmental health and chronic disease research [1].

• Chronic Fatigue Syndrome; Humidifier Disinfectant; PHMG-p; Mitochondrial Dysfunction; Blood Brain Barrier; Glymphatic System; Environmental Toxicology; Long COVID

Leem JH, Kim HC (2026) Environmental Toxic Exposure as a Trigger for Chronic Fatigue Syndrome: Mitochondrial and Neurovascular Path ways Beyond the Lung. J Drug Des Res 13(1): 1102.

The study by Yang and colleagues, “Chronic Fatigue Syndrome Induced by Environmental Toxic Exposure: Effects of Polyhexamethyleneguanidine Phosphate Exposure on Mitochondrial Function and Neural Health,” represents an important development in environmental health and chronic disease research [1]. The authors move the Korean humidifier disinfectant disaster beyond its earlier framing as a predominantly respiratory toxicology event and present evidence that exposure to polyhexamethyleneguanidine phosphate (PHMG-p) may contribute to chronic fatigue syndrome (CFS) through persistent mitochondrial and neurophysiological dysfunction [1]. This argument is significant because it connects a defined environmental exposure with a disabling chronic multisystem illness for which biological mechanisms remain incompletely understood.

The manuscript is timely for several reasons. First, it addresses an unmet scientific need in the long-term evaluation of humidifier disinfectant injury. Although acute and chronic lung injury has been central to the recognition of this disaster, previous clinical and toxicological discussions have suggested that humidifier disinfectant exposure may produce systemic effects involving oxidative stress, endothelial injury, and mitochondrial dysfunction [2]. Second, it offers a mechanistic bridge between exposed human patients and an experimental PHMG-p model. Third, it places environmentally induced CFS within a wider field of post-exposure and post-injury chronic illnesses, including ME/CFS, long COVID, Gulf War illness, and other syndromes characterized by fatigue,post-exertional worsening, neurocognitive symptoms, autonomic dysfunction, and metabolic impairment [3-5].

The study’s most compelling contribution is its translational design. Yang and colleagues examined peripheral blood mononuclear cells (PBMCs) from patients with humidifier disinfectant-associated CFS and identified abnormal mitochondrial morphology [1]. They then reproduced related abnormalities in PHMG-p-exposed mice, including altered mitochondrial morphology, reduced mitochondrial membrane potential, decreased oxidative phosphorylation-related protein expression, and changes in genes associated with mitochondrial function [1]. These findings strengthen biological plausibility by linking human observation with experimental toxicology. They also support the broader proposition that PBMC mitochondrial phenotypes may serve as accessible indicators of systemic bioenergetic dysfunction in chronic illness.

This mitochondrial emphasis is consistent with a growing ME/CFS literature. Proteomic analysis of PBMCs from ME/CFS patients has shown altered expression of proteins involved in mitochondrial function, oxidative phosphorylation, electron transport chain complexes, and redox regulation [3]. Broader reviews of ME/CFS also emphasize immune dysregulation, impaired energy metabolism, and post-exertional malaise as central biological features rather than nonspecific complaints [4]. The PHMG-p study therefore contributes something distinctive: it identifies a concrete environmental exposure that can be experimentally associated with biological domains already implicated in ME/CFS. This helps shift environmentally associated CFS from a descriptive clinical category toward a testable mechanistic subtype.

A second important aspect of the manuscript is its focus on central regulatory systems. The authors report fatigue like behavioral changes in PHMG-p-exposed mice without evidence that the changes were simply due to peripheral muscle weakness [1]. They also describe reduced oxidative phosphorylation-related protein expression in the hypothalamus, evidence of blood-brain barrier (BBB) disruption, altered astrocytic and glymphatic markers, and exaggerated corticosterone responses after forced exercise [1]. These findings are highly relevant because the hypothalamus integrates energy balance, stress response, autonomic regulation, sleep-wake rhythms, endocrine signaling, and immune-neural communication. In a condition such as CFS, where symptoms span fatigue, cognition, sleep, autonomic function, and post-exertional symptom exacerbation, hypothalamic and neurovascular pathways deserve close attention.

The neurovascular findings also align with earlier hypotheses and imaging studies in CFS. BBB permeability has previously been proposed as a possible contributor to neurological findings in CFS [6]. Glial activation and astrocyte-related pathways have also been discussed as potential mechanisms linking immune activation with fatigue and neuropsychiatric symptoms [7]. Brain MRI studies have reported abnormal autonomic correlations in brainstem vasomotor regions and related regulatory networks in CFS [8]. The Yang et al. study adds an environmental toxicology dimension to this neuroimmune and neurovascular framework. It suggests that PHMG-p exposure may disturb not only peripheral cellular energy metabolism but also central homeostatic circuits that regulate fatigue perception, stress response, and recovery after exertion.

This conceptual shift has implications beyond PHMG-p. Toxicology has traditionally emphasized acute toxicity, organ-specific pathology, carcinogenicity, reproductive toxicity, and mortality. However, many environmental disasters produce long-lasting symptoms that do not fit neatly into conventional toxicological endpoints. Animal studies of PHMG-p inhalation have shown persistent pulmonary inflammation and fibrosis after exposure cessation, supporting the principle that humidifier disinfectant injury may have long recovery-period consequences [9]. The new study extends this logic by showing that mitochondrial and neurophysiological changes may also persist and may contribute to chronic fatigue-like illness [1].

The manuscript also provides a framework for studying other chronic diseases that may follow environmental, infectious, or occupational exposures. An adverse outcome pathway review of humidifier disinfectant substances reported that PHMG-p may induce ATP depletion, endoplasmic reticulum stress, epithelial-mesenchymal transition, inflammation, and fibrosis, while related disinfectant substances may induce mitochondrial reactive oxygen species, oxidative stress, mitochondrial dysfunction, and cell death [10]. These mechanisms are not unique to lung disease. They are relevant to chronic inflammatory, neurovascular, metabolic, and fatigue related illnesses. If environmental agents can produce persistent changes in mitochondrial energetics, barrier integrity, glial regulation, and stress-response pathways, then delayed chronic disease should become an explicit endpoint in environmental health research.

Long COVID provides a useful parallel. Persistent fatigue, cognitive impairment, post-exertional symptom exacerbation, dysautonomia, endothelial dysfunction, and multisystem symptoms are common concerns in long COVID, and recent reviews increasingly discuss mitochondrial dysfunction as a candidate mechanism linking energy deficits, oxidative stress, immune dysregulation, and persistent symptoms [5]. The PHMG-p model is not a viral model, but it shares an important logic with post-infectious illness: an initiating exposure may produce persistent biological dysregulation long after the initial insult has passed. This suggests that ME/CFS, long COVID, toxicant-associated illness, and other post-injury syndromes may partly converge on metabolic-immune neurovascular pathways, even when their initiating triggers differ.

Gulf War illness provides another relevant comparison. A recent study found decreased mitochondrial respiratory function and decreased glycolytic activity in PBMCs from veterans with Gulf War illness, supporting the broader possibility that exposure-associated chronic syndromes can involve measurable bioenergetic impairment [11]. Such findings do not imply that these illnesses are identical. Rather, they suggest that comparative research across exposure-associated syndromes may identify shared biomarkers, divergent subtypes, and convergent therapeutic targets. The Yang et al. study therefore should be read not only as a PHMG-p toxicology paper but also as part of an emerging cross-disease research agenda focused on mitochondrial, immune, neurovascular, and autonomic dysfunction.

Several limitations should be acknowledged. CFS is heterogeneous, and no animal model can fully reproduce the complexity of human ME/CFS. The PHMG-p mouse model includes persistent pulmonary pathology, which may distinguish environmentally induced CFS from classic ME/CFS cases without overt organ injury [1]. Differences in age, exposure history, comorbidity, and recovery interval between human patients and experimental animals also limit direct translation. In addition, the study does not definitively establish whether PHMG-p crosses the BBB or directly binds AQP4 in vivo [1]. These limitations do not negate the study’s contribution. Instead, they define the next phase of research.

Future studies should pursue at least four priorities. First, longitudinal cohort studies of exposed populations should evaluate whether PBMC mitochondrial abnormalities predict persistent fatigue, post-exertional malaise, autonomic dysfunction, cognitive symptoms, or recovery trajectories. Second, mechanistic studies should clarify whether PHMG-p directly affects BBB integrity, astrocyte function, AQP4 localization, glymphatic flow, hypothalamic metabolism, and HPA-axis reactivity. Third, comparative studies should examine whether similar mitochondrial and neurovascular signatures appear in long COVID, post-infectious ME/CFS, Gulf War illness, pesticide-related illness, and other toxicant-associated syndromes. Fourth, therapeutic studies should test whether interventions targeting mitochondrial function, oxidative stress, neurovascular integrity, sleep-glymphatic regulation, or autonomic balance can modify disease course in environmentally induced CFS.

The policy implications are substantial. Environmental regulation and disaster response should not end with the identification of acute organ injury. Long-term surveillance should include fatigue, post-exertional symptom exacerbation, sleep disturbance, neurocognitive symptoms, autonomic impairment, and dysfunction, immune-metabolic quality-of-life biomarkers. Such monitoring is essential for victim recognition, compensation, rehabilitation, and prevention. The PHMG-p experience also suggests that environmental health policy should adopt a more precautionary view of consumer chemical exposure, especially for agents capable of inducing oxidative stress, mitochondrial injury, epithelial barrier disruption, or systemic inflammatory effects.

In conclusion, the study by Yang and colleagues provides a biologically plausible model linking PHMG-p exposure to CFS through mitochondrial dysfunction,fatigue-like behavior, BBB disruption, hypothalamic oxidative phosphorylation impairment, glymphatic alteration, and HPA-axis dysregulation [1]. Its broader importance lies in showing how a defined environmental toxicant may contribute to chronic multisystem illness. Recognizing environmentally triggered CFS as a testable subtype could reshape research on ME/CFS, long COVID, and exposure-associated chronic disease by encouraging exposure-informed diagnosis, biomarker development, longitudinal monitoring, and preventive environmental health policy.

1. Yang HS, Lee JS, Kang MH, Song MK, Kang JY, Kim HD, et al. Chronic fatigue syndrome induced by environmental toxic exposure: Effects of polyhexamethyleneguanidine phosphate exposure on mitochondrial function and neural health. Environ Res. 2026; 295: 123874.
2. Leem JH, Kim HC. Mitochondria disease due to humidifier disinfectants: diagnostic criteria and its evidences. Environ Anal Health Toxicol. 2020; 35: e2020007.
3. Sweetman E, Kleffmann T, Edgar C, de Lange M, Vallings R, Tate W. A SWATH-MS analysis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome peripheral blood mononuclear cell proteomes reveals mitochondrial dysfunction. J Transl Med. 2020; 18: 365.
4. Toogood PL, Clauw DJ, Phadke S, Hoffman D. Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): Where will the drugs come from? Pharmacol Res. 2021; 165: 105465.
5. Molnar T, Lehoczki A, Fekete M, Varnai R, Zavori L, Erdo-Bonyar S, et al. Mitochondrial dysfunction in long COVID: mechanisms, consequences, and potential therapeutic approaches. Geroscience. 2024; 46: 5267-5286.
6. Bested AC, Saunders PR, Logan AC. Chronic fatigue syndrome: neurological findings may be related to blood--brain barrier permeability. Med Hypotheses. 2001; 57: 231-237.
7. Noda M, Ifuku M, Hossain MS, Katafuchi T. Glial Activation and Expression of the Serotonin Transporter in Chronic Fatigue Syndrome. Front Psychiatry. 2018; 9: 589.
8. Barnden LR, Kwiatek R, Crouch B, Burnet R, Del Fante P. Autonomic correlations with MRI are abnormal in the brainstem vasomotor centre in Chronic Fatigue Syndrome. NeuroImage: Clinical. 2016; 11: 530-537.
9. Yang HS, Yang M, Kang M, Kim B, Lee K. Inhalation toxicity of polyhexamethylene guanidine-phosphate in rats: A 4-week inhalation exposure and 24-week recovery period study. Chemosphere. 2023; 312: 137232.
10. Kim D, Shin Y, Park JI, Lim D, Choi H, Choi S, et al. A systematic review and BMD modeling approach to develop an AOP for humidifier disinfectant-induced pulmonary fibrosis and cell death. Chemosphere. 2024; 364: 143010.
11. Meyer JN, Pan WK, Ryde IT, Alexander T, Klein-Adams JC, Ndirangu DS, et al. Bioenergetic function is decreased in peripheral blood mononuclear cells of veterans with Gulf War Illness. PLoS One. 2023; 18: e0287412.